In vitro metabolism of eupatilin by multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes

References

• Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P450 3A and 2C9. Xenobiotica 1995; 25: 261–270
   PubMed Web of Science ®Google Scholar
• Cheng Z, Radominska-Pandya A, Tephly TR. Cloning and expression of human UDP-glucuronosyltransferse (UGT) 1A8. Archives of Biochemistry and Biophysics 1998; 356: 301–305
   PubMed Web of Science ®Google Scholar
• Galijatovic A, Otake Y, Walle UK, Walle T. Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells-potential role in Caco-2 cells-potential role in carcinogen bioinactivation. Pharmaceutical Research 2001; 18: 374–379
   PubMed Web of Science ®Google Scholar
• Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics Journal 2003; 3: 136–158
   PubMed Web of Science ®Google Scholar
• Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S, Di Rienzo A, Ratain MJ. Phenotype–genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clinical Pharmacology and Therapeutics 1999; 65: 576–582
   PubMed Web of Science ®Google Scholar
• Jang JM, Park KJ, Kim DG, Shim HJ, Ahn BO, Kim SH, Kim WB. Pharmacokinetics of a new antigastric agent, eupatilin, an active component of Stillen®, in rats. Journal of Applied Pharmacology 2003; 11: 163–168
   Google Scholar
• Ji HY, Lee HW, Shim HJ, Kim SH, Kim WB, Lee HS. Metabolism of eupatilin in rats using liquid chromatography/electrospray mass spectrometry. Biomedical Chromatography 2004; 18: 173–177
   PubMed Web of Science ®Google Scholar
• Kiang TKL, Ensom MHH, Chang TKH. UDP-glucuronosyltransferses and clinical drug–drug interactions. Pharmacology and Therapeutics 2005; 106: 97–132
   PubMed Web of Science ®Google Scholar
• Kim AR, Zou YN, Park TH, Shim KH, Kim MS, Kim ND, Kim JD, Bae SJ, Choi JS, Chung HY. Active components from Artemisia iwayomogi displaying ONOO(–) scavenging activity. Phytotherapy Research 2004; 18: 1–7
   PubMed Web of Science ®Google Scholar
• Kim MJ, Kim DH, Na HK, Oh TY, Shin CY, Surh YJ. Eupatilin a pharmacologically active flavone derived from Artemisia plants, induces apoptosis in human gastric cancer (AGS) cells. Journal of Environmental Pathology and Toxicological Oncology 2005a; 24: 261–269
   PubMed Web of Science ®Google Scholar
• Kim JY, Kwon EY, Lee YS, Kim WB, Ro JY. Eupatilin blocks mediator release via tyrosine kinase inhibition in activated guinea pig lung mast cells. Journal of Toxicology and Environmental Health 2005b; 2063–2080, Part A 68
   Web of Science ®Google Scholar
• Koshihara Y, Neichi T, Murota S, Lao A, Fujimoto Y, Tatsuno T. Selective inhibition of 5-lipoxygenase by natural compounds isolated from Chinese plants. Artemiae rubripes Nakai. FEBS Letters 1983; 1158: 41–44
   Web of Science ®Google Scholar
• Miners JO, McKinnon RA. CYP1A. Metabolic drug interactions, RH Levy, KE Thummel, WF Trager, PD Hansten, M Eichelbaum. Lippincott Williams & Wilkins, Philadelphia, PA 2000; 61–73
   Google Scholar
• Miners JO, Knight KM, Houston JB, Mackenzie PI. In vitro–in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochemical Pharmacology 2006; 71: 1531–1539
   PubMed Web of Science ®Google Scholar
• Naganuma M, Saruwatari A, Okamura S, Tamura H. Turmeric and curcumin modulate the conjugation of 1-naphtol in Caco-2 cells. Biological and Pharmaceutical Bulletin 2006; 29: 1476–1479
   PubMed Web of Science ®Google Scholar
• Newton DJ, Wang RW, Lu AY. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition 1995; 23: 154–158
   PubMed Web of Science ®Google Scholar
• Park SC, Yoon JH, Kim W, Gwak G-Y, Kim KM, Lee SH, Lee S-M, Lee H-S. Eupatilin attenuates bile acid-induced hepatocyte apoptosis. Journal of Gastroenterology 2006; 41: 772–778
   PubMed Web of Science ®Google Scholar
• Rae JM, Soukhova NV, Flockhart DA, Desta Z. Triethylenethiophosphamide is a specific inhibitor of cytochrome P-450 2B6: Implications for cyclophosphamide metabolism. Drug Metabolism and Disposition 2002; 30: 520–530
   Web of Science ®Google Scholar
• Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, Goldstein JA. Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 1993; 3: 239–249
   PubMedGoogle Scholar
• Seo HJ, Surh YJ. Eupatilin, a pharmacologically active flavone derived from Artemisia plants, induces apoptosis in human promyelocytic leukemia cells. Mutation Research 2001; 496: 191–198
   PubMed Web of Science ®Google Scholar
• Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, De la Torre R, Davies DS. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. British Journal of Clinical Pharmacology 1990; 29: 651–663
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Shipkova M, Wieland E. Glucuronidation in therapeutic drug monitoring. Clinica Chimica Acta 2005; 358: 2–23
   PubMed Web of Science ®Google Scholar
• Strassburg CP, Oldhafer K, Manns MP, Tukey RH. Differential expression of the UGT1A locus in human liver, biliary and gastric tissue: Identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissues. Molecular Pharmacology 1997; 52: 212–220
   PubMed Web of Science ®Google Scholar
• Suzuki H, Kneller MB, Haining RL, Trager WF, Rettie AE. (+)-N-3-benzyl-nirvanol and (–)-N-3-benzyl-phenobarbital: New potent and selective in vitro inhibitors of CYP2C19. Drug Metabolism and Disposition 2002; 30: 235–239
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Relative quantities of catalytically active CYP2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach. Journal of Pharmaceutical Science 1998; 87: 845–853
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS, Gaman EA, Gleeson JPR, Proctor WR. Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metabolism and Disposition 2005; 33: 413–418
   PubMed Web of Science ®Google Scholar
• Yun CH, Shimada T, Guengerich FP. Purification and characterization of human liver microsomal cytochrome P450 2A6. Molecular Pharmacology 1991; 40: 679–685
   Google Scholar
• Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP-glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metabolism and Disposition 2005; 33: 1729–1739
   PubMed Web of Science ®Google Scholar